I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on

Atty Dkt No. 8350-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

John W. SHELL

Serial No.: 10/052,712

Filing Date: January 17, 2002

Group Art Unit: 1614

Examiner: Unassigned

Title: METHOD FOR IDENTIFYING COMPOUNDS TO TREAT MEDICAL

MAR 2 5 2002

PATHOLOGIES ASSOCIATED WITH MOLECULAR CRYSTALLIZATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. Applicant respectfully requests that the Examiner review and make of record the references identified below.

A PTO-1449 form listing the references accompanies this paper. Applicant would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

OTHER DOCUMENTS

Bernardini et al. (1981), "Gap Junction Crystallization in Lens Fibers After an Increase in Cell Calcium," Invest. Ophthalmol. Vis. Sci. 21(2):291-299.

Brooks et al. (1994), "Crystalline Nature of the Iridescent Particles in Hypermature Cataracts," Br. J. Ophth. 78(7):581-58.

Keulemans et al. (1999), "Concanavalin A-Binding Cholesterol Crystallization Inhibiting and Promoting Activity in Bile from Patients with Crohn's Disease Compared to Patients with Ulcerative Colitis," Journal of Hepatology 31:685-691.

Secknus et al. (1996), "Purification and Characterization of a Novel Human 15 kd Cholesterol Crystallization Inhibitor Protein in Bile," J. Lab. Clin. Med. 127(2):169-178.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

Atty Dkt No. 8350-0001 Serial No. 10/052,712

As applicant has not yet received a first Action on the merits, no fee is required for filing this Supplemental Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 18-0580 may be charged therefor. A duplicate copy of this paper is enclosed.

Respectfully submitted,

Date

By:

Dianne E. Reed

Registration No. 31,292

REED & ASSOCIATES 800 Menlo Avenue, Suite 210 Menlo Park, California 94025 (605) 330-0900 Telephone (650) 330-0980 Facsimile

	<u>.</u>		_1_1
SUBSTITUTE	EODM	DTO	1440
CODSTITUTE	LOWN	FIO-	1449
(MODIFIED)			
(MIODILIED)			

_						
U.S.	EPARTI	MENT	OF	COM	MERC	E
	T AND					

ATTY.	DOC	ET NO.:
	8350	0-0001

Page 1 of 1 SERIAL NO.: 10/052,712

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

APPLICANT: John W. SHELL

LING DATE:

January 17, 2002

GROUP: 1614

(37 CFR 1.98(b))

		OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS
EXAMINER INITIALS	CITE NO.	INCLUDE NAME OF AUTHOR, TITLE OF ARTICLE (IF APPROPRIATE), TITLE OF PUBLICATION, DATE, PAGE(S), VOLUME-ISSUE NUMBER(S), PUBLISHER, AND PLACE OF PUBLICATION
	AY	Bernardini et al. (1981), "Gap Junction Crystallization in Lens Fibers After an Increase in Cell Calcium," <i>Invest. Ophthalmol. Vis. Sci.</i> 21(2):291-299.
	AZ	Brooks et al. (1994), "Crystalline Nature of the Iridescent Particles in Hypermature Cataracts," Br. J. Ophth. 78(7):581-58.
	BA	Keulemans et al. (1999), "Concanavalin A-Binding Cholesterol Crystallization Inhibiting and Promoting Activity in Bile from Patients with Crohn's Disease Compared to Patients with Ulcerative Colitis," <i>Journal of Hepatology</i> 31:685-691.
	BB	Secknus et al. (1996), "Purification and Characterization of a Novel Human 15 kd Cholesterol Crystallization Inhibitor Protein in Bile," <i>J. Lab. Clin. Med.</i> 127(2):169-178.

MAR 2 5 2002

TECH CENTER 1600/2900 APR 0 1 2002

EXAMINER SIGNATURE:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.